胶质母细胞瘤的血管生成机制及抗血管生成药物研究进展  

Recent advance in angiogenesis mechanism and drug option of glioblastoma

作　　者：袁航[1] 闫秀伟 胡韶山 Yuan Hang;Yan Xiuwei;Hu Shaoshan(Department of Neurosurgery,Zhejiang Provincial People's Hospital,Hangzhou 310016,China)

机构地区：[1]浙江省人民医院神经外科,杭州310016

出　　处：《中华神经医学杂志》2025年第1期88-93,共6页Chinese Journal of Neuromedicine

摘　　要：胶质母细胞瘤(GBM)是中枢神经系统中常见的恶性肿瘤之一,其显著特征是过度血管生成。抗血管生成药物可通过抑制GBM的血管生成来发挥其治疗效果,但复发GBM的血管生成机制与原发GBM不同,可能绕过血管内皮生长因子(VEGF)途径,通过其他途径形成新的血管,因此,抗血管生成药物对复发GBM的疗效较差。本文围绕GBM复发前后的血管生成机制及抗血管生成药物的研究进展进行综述,以期为GBM的治疗提供参考。Glioblastoma(GBM)is one of the common malignant tumors in central nervous system,characterized by excessive angiogenesis.Anti-angiogenic therapeutic drug can improve the therapeutic effect on GBM by inhibiting angiogenesis.However,the mechanisms of angiogenesis in recurrent GBM differ from those in primary GBM,potentially bypassing the vascular endothelial growth factor(VEGF)pathway and forming new blood vessels through alternative routes,thereby the efficacy of anti-angiogenic drug is often poor in recurrent GBM.This review focuses on research progress in angiogenesis mechanism before and after GBM recurrence and provides references for GBM treatment.

关 键 词：胶质母细胞瘤 血管生成 血管内皮生长因子 

分 类 号：R739.4[医药卫生—肿瘤]